StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.16−0.02 (-0.28%)

Close on Nov 20, 2026Market cap $472.65MP/E –Yield –

Regenxbio shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Regenxbio's shares outstanding was 53M at Jun 30, 2026. For fiscal 2025 it was 52M, up 4.2% from the year before. Over ten years it grew 18.8% a year on average. The highest annual figure on record is 52M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202552M+4.2%
FY2024Dec 31, 202450M+13.2%
FY2023Dec 31, 202344M+1.3%
FY2022Dec 31, 202243M-1.7%
FY2021Dec 31, 202144M+17.8%
FY2020Dec 31, 202037M+1.6%
FY2019Dec 31, 201937M+0.1%
FY2018Dec 31, 201837M+22.7%
FY2017Dec 31, 201730M+13.1%
FY2016Dec 31, 201626M+187.9%
FY2015Dec 31, 20159M+247.1%
FY2014Dec 31, 20143M+13.9%
FY2013Dec 31, 20132M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202653M+3.0%
Q1 FY2026Mar 31, 202652M+1.9%
Q4 FY2025Dec 31, 202552M+1.7%
Q3 FY2025Sep 30, 202552M+1.8%
Q2 FY2025Jun 30, 202551M+1.7%
Q1 FY2025Mar 31, 202551M+12.5%
Q4 FY2024Dec 31, 202451M+15.6%
Q3 FY2024Sep 30, 202451M+15.6%
Q2 FY2024Jun 30, 202451M+16.2%
Q1 FY2024Mar 31, 202446M+5.3%
Q4 FY2023Dec 31, 202344M+101641.0%
Q3 FY2023Sep 30, 202344M+101834.5%
Q2 FY2023Jun 30, 202344M+101266.9%
Q1 FY2023Mar 31, 202343M-10.7%
Q3 FY2022Sep 30, 20220M+1.5%
Q2 FY2022Jun 30, 20220M+1.4%
Q1 FY2022Mar 31, 20220M+2.7%
Q4 FY2021Dec 31, 202149M+30.1%
Q3 FY2021Sep 30, 20210M-99.9%
Q2 FY2021Jun 30, 20210M-99.9%
Q1 FY2021Mar 31, 20210M-99.9%
Q4 FY2020Dec 31, 202037M+1.4%
Q3 FY2020Sep 30, 202039M+5.6%
Q2 FY2020Jun 30, 202037M+1.6%
Q1 FY2020Mar 31, 202037M+2.0%
Q4 FY2019Dec 31, 201937M-5.3%
Q3 FY2019Sep 30, 201937M+8.3%
Q2 FY2019Jun 30, 201937M+4.0%
Q1 FY2019Mar 31, 201936M+6.1%
Q4 FY2018Dec 31, 201839M+24.9%
Q3 FY2018Sep 30, 201834M+9.9%
Q2 FY2018Jun 30, 201835M+15.0%
Q1 FY2018Mar 31, 201834M+28.5%
Q4 FY2017Dec 31, 201731M+17.8%
Q3 FY2017Sep 30, 201731M+16.9%
Q2 FY2017Jun 30, 201731M–
Q1 FY2017Mar 31, 201727M–
Q4 FY2016Dec 31, 201626M–
Q3 FY2016Sep 30, 201626M–

More Regenxbio figures

See a number that looks wrong?